James E. Muntz, MD
Dr. James Muntz is a Professor in the Department of Orthopedic Surgery at McGovern Medical School at UTHealth Houston.
Certified by the American Board of Internal Medicine, Dr. Muntz specializes in Internal Medicine with an emphasis in Sports Medicine injuries and conditions. Involved in various sponsored research, Dr. Muntz has presented his findings on venous thrombosis at more than 600 conferences and has been interviewed by the television networks ABC, NBC, ESPN and CNN in regards to his sports affiliations. He is currently medical team physician for the NBA Houston Rockets, the Houston Astros major league baseball, and team internal medicine physician for the NFL Houston Texans.
Dr. Muntz received his undergraduate degree from Indiana University in Bloomington, Indiana. He attended medical school at Baylor College of Medicine in Houston, Texas. Dr. Muntz completed his internship at St. Luke’s Episcopal Hospital Program and his residency at Baylor College of Medicine in Houston, Texas.
Dr. Muntz is a member of several professional organizations, including the American College of Physicians, the International Society of Thrombosis and Hemostasis, and the American College of Sports Medicine.
- Undergraduate Degree
- Indiana University, Bloomington, Indiana
- Medical School
- Baylor College of Medicine, Houston, Texas
- St. Luke's Episcopal Program, Houston, Texas
- Baylor College of Medicine, Houston, Texas
Areas of Interest
Double Blind Randomized Placebo Control Study to Determine the Effectiveness and Safety of Migramist (Dihydroergotamine Mesylate Nasal Spray) 2 milligrams for Acute Treatment of Acute Migraine Headaches with or without Aura in Migraineur Families. Chairperson: Robert Rees, M.D. Dr. Muntz, Investigator #MU/TX-793-42. Study is Clinical Trial Study #793-42. Protocol DHE454.
The Effectiveness and Safety of Subcutaneous Enoxaparin compared to Intravenous Unfractionated Heparin for Patients Presenting with Unstable Angina or Non-Q Wave MI: An international double blind randomized parallel group, multi-center study (TIMI 11B). Protocol #RP54563-308. Regulatory #IND 31, 532. Sponsor: Rhone-Poulenc, Rorer Pharmaceuticals, Inc. Sub-Investigator.
A multicenter, randomized, parallel, assessor blind dose ranging study of subcutaneous SR90107A/ ORG31540 with a comparative control group of subcutaneous low molecular weight heparin in the prevention of deep vein thrombosis after elective total hip replacement. Principal Investigator, Houston, Texas, James E. Muntz, M.D.
An Analysis of Blood management in Patients Undergoing Total Hip & Knee Surgery (The O.R.T.H.O. Initiative); with Ortho Biotech in JBJS, 1/1999.
Organon Knee: A multicenter, multinational, randomized, double-blind, comparison of subcutaneous ORG31540/SR90107A, Study 095002, with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective major knee surgery or a revision. Principal Investigator, Houston, Texas, James E. Muntz, M.D.
A multicenter, multinational, randomized, double-blind, comparison of subcutaneous ORG31540/ SR90107A, Protocol N EFC2442, with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective hip replacement or a revision. Principal Investigator, Houston, Texas, James E. Muntz, M.D.
A Multicenter, Randomized, Double-Blind Study comparing the Efficacy and safety of once daily (O.D.) R90107A/ORG 31540 versus twice daily (B.I.D) Enoxaparin in the Initial Treatment of acute symptomatic deep vein Thrombosis (DVT) protocol. Protocol Number EFC 2441.
A Randomized, Double–Blind, Comparative Study of H376/95 and Warfarin (Coumadin®) for the Prevention of Venous Thromboembolism following Total Knee Arthroplasty. Protocol No: 236.
A Phase II, Multicenter, Randomized, Open-Label Prospective Study to Evaluate Tinzaparin Versus Unfractionated Heparin In Subjects Who Are Receiving Long Term Warfarin and Require Parenteral Anticoagulation after the Discontinuation of Warfarin Therapy for an Invasive or Surgical Procedure.
A Phase II, Randomized, Double-Blind, Active Controlled (Enoxaparin), Parallel Group, Dose-Response Study of DPC 906 for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery.
A Randomized, Double-Blind, Multicenter Study Comparing the Safety and Efficacy of Two Dosing Regimens of Oral EMISPHERETM SNAC/Heparin with Subcutaneous Enoxaparin Sodium for the Prevention of Venous Thromboembolic Events Following Elective Total Hip Replacement Surgery.
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Single-Dose, Subcutaneous (SC) Darbepoetin Alfa in Subjects Undergoing Preoperative Autologous Blood Donation (PAD) Before Elective Revision Total Hip Replacement or Bilateral Knee Replacement Surgery.
A Multicenter, Randomized, Double-Blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolic Events in High Risk Patients Undergoing Abdominal Surgery. Sanofi-Synthelabo Protocol No: EFC3558.
A Randomized, Placebo-Controlled, Double-Blind, Pilot Study Comparing the Safety and Efficacy of the Use of Enoxaparin (Lovenox®) for Prophylaxis for the Prevention of Deep Vein Thrombosis after Arthroscopic Knee Surgery.
A multicentre, Open-label, Dose Response (Phase IIa) Study of ART-123 (Recombinant Human Soluble Thrombomodulin) by Subcutaneous Injection in the Prevention of Postoperative Venous Thrombosis in Patients Undergoing Elective, Unilateral Total Hip Replacement. Protocol No. A01-1329.
VanGogh DVT Trial – A multicenter international randomized open label, assessor blind non-inferiority study comparing the efficacy and safety of once weekly subcutaneous SAN and ORG 34006 with a combination of low molecular weight heparin and vitamin K antagonist in the treatment of acute symptomatic deep venous thrombosis.
VanGogh Pulmonary Embolism Trial – A multicenter international randomized open label, assessor blind non-inferiority study in the treatment of acute symptomatic pulmonary embolism.
A multicenter international randomized open label, double blind study comparing the efficacy and safety of once weekly subcutaneous SAN ORG with placebo in the long-term prevention of symptomatic venous thromboembolism in patients with symptomatic pulmonary embolism or deep venous thrombosis who completed 6 months of treatment with vitamin K antagonist or SAN ORG 34006.
Catheter-directed intra-thrombus thrombolysis with Urokinase and anticoagulation versus anticoagulation alone for acute iliofemoral venous thrombosis: A multicenter international randomized trial. Thrombolysis of Lower Extremity Deep Venous Thrombosis Or Anticoagulation. Principal Investigator: Alan Lumsden, MD. Co-Investigator: James E. Muntz, MD.
Protocol A5571010: A phase 2B randomized, multicenter, dose-ranging study assessing the safety and efficacy of PD 0348292 in the prevention of venous thromboembolic events (VTE) in subjects undergoing an elective, unilateral total knee replacement.
Protocol 1160.24: RE-MOBILIZE. A Phase III Randomized, Parallel-Group, Double-Blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150mg Day 2 – Completion, and 110mg Day 1 Followed by 220mg Day 2 – Completion) of Dabigatran Etexilate Administered Orally (Capsules), Compared to Enoxaparin 30mg Twice a Day Subcutaneously for 12-15 Days, in Prevention of Venous Thromboembolism in Patients with Primary Elective Total Knee Replacement Surgery (RE-MOBILIZE).
Protocol ITI101724: A Fibrillation Rapid Trials. A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250 mg, 372 mg and 500 mg) administered twice daily for 16 weeks, on top of aspirin (325 mg, qd) in men and women with non valvular atrial fibrillation at a low or intermediate risk for stroke.
Protocol CV185-010: A Phase 2 Randomized, Double-Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery.
Peer Reviewed Articles
Muntz, JE, Perioperative Deep Venous Thrombosis and Pulmonary Embolism: Diagnosis, Management, and Treatment. National Association of Orthopedic Nurses (magazine): March/April 1997 supplement pages 25-29
Muntz, JE, Safe and Effective Use of Low Molecular Weight Heparin to Prevent Deep Venous Thrombosis in Orthopedic Patients.. Release date: November 1999.
Muntz, JE, Advances in the Prevention and Treatment of Thrombotic Complications in the Rehabilitation Patient, Wednesday November 10, 1999, Washington D.C.
Muntz, JE, : “Deep Vein Thrombosis and Pulmonary Embolism in the Perioperative Patient. American Journal of Managed Care: November 2000
Muntz, JE, Surgical Rounds; Risk Assessment Anticoagulation General Surgery Patient. Venous Thromboembolism – Bridging Therapy with Anticoagulation; pp. 9-11; October 2000.
Muntz, JE, Scientia Magazine; Guest Editor. Publication; Atherosclerosis and Thrombosis. February 2001.
McCuthen, J.; Muntz JE ; Louis M. Kwong LM; Lassen MR; New Therapies: Selective Clotting Factor Inhibition Venous Thromboembolic Disease After Orthopedic Surgery: Highlights Newsletter, March 2001 Breakthroughs in Prophylaxis December 15, 2000.
Muntz JE, Turpie AG, Ken Bauer K, Eriksson B, et al “The First Synthetic Factor Anti XA Inhibitor, Pentasaccharide (Arixtra) Compared with Low Molecular Weight Heparin to Prevent Venous Thromboembolism,” pages 119 and 120. Southern Orthopedic Association, Summer 2001, vol. 10, No. 2
Muntz, JE. Optimizing Antithrombotic Therapy for Venous Thromboembolism Prophylaxis: The American Journal of Orthopedics, April 2002 Supplement, vol. XXXI, No. 4S
Kwong LM, Muntz JE: Thromboprophylaxis Dosing: The Relationship Between Timing of First Administration, Efficacy and Safety, Pages 16-20, The American Journal of Orthopedic Surgery, November 2002 Supplement, vol. XXXI, No. 11S
Muntz JE; Risks of Venous Thrombosis in Non-Large Joint Surgery. American Journal of Orthopedic Surgery February 2003, Vol 26 Number 2 Supplement pages 1-6.
Muntz JE; Orthopedic Pearls in Deep Vein Thrombosis: Questions Frequently Asked: Journal of Surgical Orthopedic Advances, Winter 2003, vol. 12, number 12, number 4, pages 225-227
Sean Sullivan, MD, Bruce Davidson, MD, Susan Khan, MD and James E. Muntz, MD, et al Cost Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism Using Patients Undergoing Major Orthopedic Surgery: Pharmacoeconomics 2003; 22 (9): 605-620
Muntz JE Major Bleeding Rates After Prophylaxis Against Venous Thromboembolism: Systemic Review Meta Analysis and Cost Implications: International Journal of Technology Assessment and Healthcare, 20:4 (2004), 405-414, copyright 2004, Cambridge University Press, printed in the USA
Muntz, JE, O’Conner PJ, Yin H, Vogenberg FR. Factors associated with thromboprophylaxis for orthopedic patients and their impact on outcome. Amer J of Orthopedics. 2007 April 3, 2007 (4), 193-197.
Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE; Apollo Investigators. Fondaparinux combined with intermittent pneumatic compression vs. intermittent compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double blind comparison. J Thrombosis and Hemostasis 2007 Sept. 5 (9) 1854-61.
James Muntz, M.D. Thromboprophylaxis in Orthopedic Surgery: How long Is Long Enough? The American Journal of Orthopedics. 2009 August, 32-35.
James E. Muntz, M.D., Franklin A. Michota, M.D. Prevention and Management of Venous Thromboembolism in the surgical patient: Options by surgery type and individual patient risk factors. The American Journal of Orthopedics. 2010 January, S11-20.
James E. Muntz, M.D., Franklin A. Michota, M.D. Prevention and Management of Venous Thromboembolism in the surgical patient: Options by surgery type and individual patient risk factors, The American Journal of Surgery, November 2010 Supplement, Vol. 199, No. 1A
James Muntz, M.D. Duration of DVT prophylaxis in the surgical patient and its relation to quality issues, The American Journal of Surgery, 2010
James Muntz, M.D. Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Total Hip Arthroplasty: The Promise of New Oral Anticoagulants, The Journal of Surgical Orthopedic Advances, Volume 20, Number 4, Winter 2011
Books and Chapters
Muntz, JE. Techniques in Orthopedics. 19 (4): 000-000, 2004, Lippincott, Williams and Wilkins
Muntz, JE. Techniques in Orthopedics, December 2004. Treatment of Venous Thromboembolism in Orthopedic Surgery
Muntz, JE. Techniques in Orthopedics, December 2004 Fondaparinux for Prophylaxis in Orthopedic Surgery.